Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

772 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.
Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, Graf N, Klingebiel T, Kremens B, Lehrnbecher T, von Neuhoff C, Ritter J, Sander A, Schrauder A, von Stackelberg A, Starý J, Reinhardt D. Creutzig U, et al. Among authors: graf n. Blood. 2013 Jul 4;122(1):37-43. doi: 10.1182/blood-2013-02-484097. Epub 2013 May 23. Blood. 2013. PMID: 23704089 Free article. Clinical Trial.
12q13, a new recurrent breakpoint in acute non-lymphoblastic leukemia.
Seyger MM, Ritterbach J, Creutzig U, Gnekow AK, Göbel U, Graf N, Reiter A, Lampert F, Harbott J. Seyger MM, et al. Among authors: graf n. Cancer Genet Cytogenet. 1995 Mar;80(1):23-8. doi: 10.1016/0165-4608(94)00157-7. Cancer Genet Cytogenet. 1995. PMID: 7697629
[NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphomas in children and adolescents. Part 2: An intermediate term analysis of the non-B-NHL therapy group. BFM Study group].
Reiter A, Schrappe M, Yakisan E, Sauter S, Henzler D, Zimmermann M, Graf N, Fengler R, Kühl J, Fleischhack G, et al. Reiter A, et al. Among authors: graf n. Klin Padiatr. 1994 Jul-Aug;206(4):234-41. doi: 10.1055/s-2008-1046609. Klin Padiatr. 1994. PMID: 7967419 Clinical Trial. German.
Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Münster Group.
Dördelmann M, Schrappe M, Reiter A, Zimmermann M, Graf N, Schott G, Lampert F, Harbott J, Niemeyer C, Ritter J, Dörffel W, Nessler G, Kühl J, Riehm H. Dördelmann M, et al. Among authors: graf n. Leukemia. 1998 May;12(5):645-51. doi: 10.1038/sj.leu.2400989. Leukemia. 1998. PMID: 9593260
IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.
Fleischhack G, Hasan C, Graf N, Mann G, Bode U. Fleischhack G, et al. Among authors: graf n. Br J Haematol. 1998 Aug;102(3):647-55. doi: 10.1046/j.1365-2141.1998.00836.x. Br J Haematol. 1998. PMID: 9722289 Free article. Clinical Trial.
Definition of a standard-risk group in children with AML.
Creutzig U, Zimmermann M, Ritter J, Henze G, Graf N, Löffler H, Schellong G. Creutzig U, et al. Among authors: graf n. Br J Haematol. 1999 Mar;104(3):630-9. doi: 10.1046/j.1365-2141.1999.01304.x. Br J Haematol. 1999. PMID: 10086807 Free article.
772 results